Beddow Capital Management Inc. Buys 14,475 Shares of Pfizer Inc. (NYSE:PFE)

Beddow Capital Management Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 9.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 168,360 shares of the biopharmaceutical company’s stock after buying an additional 14,475 shares during the period. Pfizer makes up about 2.1% of Beddow Capital Management Inc.’s portfolio, making the stock its 20th biggest holding. Beddow Capital Management Inc.’s holdings in Pfizer were worth $4,711,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Cantor Fitzgerald Investment Advisors L.P. bought a new stake in shares of Pfizer in the 4th quarter worth about $16,166,000. LGT Group Foundation boosted its position in Pfizer by 2.5% in the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after buying an additional 18,274 shares during the period. ORG Partners LLC boosted its position in Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 44,458 shares during the period. Kempner Capital Management Inc. purchased a new stake in Pfizer in the 1st quarter valued at about $2,439,000. Finally, Leo Wealth LLC purchased a new stake in Pfizer in the 4th quarter valued at about $2,171,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Down 0.8 %

PFE stock opened at $29.42 on Friday. The firm has a market cap of $166.71 billion, a PE ratio of -490.25, a P/E/G ratio of 1.05 and a beta of 0.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm’s fifty day moving average is $29.36 and its 200 day moving average is $28.22. Pfizer Inc. has a one year low of $25.20 and a one year high of $34.11.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the business earned $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.71%. Pfizer’s payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.